Objectives: The objective of this study was to assess the outcome of antimicrobial susceptibility-guided therapies in Helicobacter pylori-infected individuals who had undergone unsuccessful prior eradication treatments.
Introduction
Infections with Helicobacter pylori cause gastritis and may result in complications such as peptic ulcer disease, gastric adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma. 1 To eradicate the bacteria and prevent these complications, patients are prescribed empirical first-line antimicrobial therapies with clarithromycin and metronidazole or amoxicillin in combination with a proton pump inhibitor (PPI). 2, 3 These treatments, however, may fail due to a lack of compliance and increasing antibiotic resistance. 4, 5 Several factors drive the development of antimicrobial resistance with the number of prior treatment failures being the most important one. We recently showed that after just one unsuccessful therapy, resistance to clarithromycin rose to 60%; further vain treatment attempts resulted in resistance as high as 80%. 6 In parallel, double resistance to clarithromycin and metronidazole soared to 65% and triple resistance to clarithromycin, metronidazole and quinolones increased to 15%. 6 The German National Reference Centre (NRC) for H. pylori receives and microbiologically examines gastric tissue samples primarily from patients who had undergone unsuccessful eradication treatments in the past. Such patients frequently carry H. pylori resistant to two or more antibiotics, making treatment particularly challenging. To improve patients' prospects of successful eradication of H. pylori, the NRC supports gastroenterologists and general practitioners by testing antimicrobial susceptibility of H. pylori and giving guideline-based treatment recommendations. 2, 3 In this retrospective study, we assessed the outcome of such susceptibility-based eradication treatments in H. pylori-positive patients and whether clinical symptoms improved. We show that susceptibility testing-guided eradication therapies achieve eradication rates as high as 70% in those patients.
Methods
Patients, gastric tissue samples and microbiological examination A total of 481 H. pylori-positive patients from across Germany were retrospectively evaluated and included in the study. Patients were routinely endoscoped between 2004 and 2013 by their attending gastroenterologists. Gastric tissue samples were taken and sent to the NRC for H. pylori by using a special transport medium (Portagerm pylori, bioMé rieux, Germany) within 48 h. Data on prior eradication therapies and diagnosed gastric diseases were routinely collected from endoscopy reports.
On receipt, gastric tissue samples were crushed in 1.8 mL reaction tubes (Eppendorf, Germany) and streaked onto Columbia agar-based culture medium containing 10 vol% washed human erythrocytes and 10 vol% heat-inactivated horse serum. Culture media were then incubated under microaerobic conditions at 378C for 2 -10 days. Grown Phenotypic susceptibility to amoxicillin, metronidazole, clarithromycin, ciprofloxacin/levofloxacin and tetracycline was tested on either IsoSensitest (Oxoid, Germany) or Mueller -Hinton agar plates (with 10% horse blood; Oxoid, Germany) by using the Etest w method (bioMérieux) as described previously. 6 As there is no rifabutin Etest w available in Europe, rifampicin was used to screen for rifabutin resistance. Isolates were classified as susceptible or resistant by applying the following breakpoints: metronidazole, 8 mg/L; clarithromycin, 1 mg/L; ciprofloxacin/levofloxacin, 1 mg/L; amoxicillin, 1 mg/L; tetracycline, 1 mg/L; and rifampicin, 4 mg/L. 6 
Susceptibility-guided therapy recommendations and outcome
Treatment recommendations based on susceptibility testing were given on request in line with the German S3 guideline 2 and the Maastricht IV consensus. 3 Ahead of any recommendation, attending gastroenterologists and/or general practitioners were asked to provide information on any prior antimicrobial treatments of H. pylori and unrelated bacterial infections.
In the case of resistance to metronidazole and clarithromycin, the NRC recommended regimens consisting of: (i) PPI (twice the standard dose, three-times daily) and amoxicillin (1000 mg, three-times daily) for ≥14 days; (ii) PPI (standard dose, twice daily), amoxicillin (1000 mg, twice daily) and levofloxacin (500 mg, once daily) for 10 days; (iii) PPI (standard dose, twice daily), amoxicillin (1000 mg, twice daily) and rifabutin (150 mg, twice daily) for 10 days; (iv) PPI (standard dose, twice daily), levofloxacin (500 mg, once daily) and rifabutin (150 mg, twice daily) for 10 days; and (v) PPI (standard dose, twice daily), metronidazole (400 mg, threetimes daily), tetracycline (500 mg, four-times daily) and bismuth subcitrate (120 mg, four-times daily) for 10 days.
To eradicate triple-resistant H. pylori (resistant to metronidazole, clarithromycin and quinolones), suggested therapies included: (i) PPI (twice the standard dose, three-times daily) and amoxicillin (1000 mg, threetimes daily) for ≥14 days; (ii) PPI (standard dose, twice daily), amoxicillin (1000 mg, twice daily) and rifabutin (150 mg, twice daily) for 10 days; and (iii) PPI (standard dose, twice daily), metronidazole (400 mg, three-times daily), tetracycline (500 mg, four-times daily) and bismuth subcitrate (120 mg, four-times daily) for 10 days.
Six months on, gastroenterologists and/or general practitioners were sent questionnaires to collect information on the treatment prescribed, patients' symptoms and therapy success as tested by the urea breath test, Helicobacter urease test, stool antigen ELISA or microbiology and/or histopathology. In line with national and international guidelines, 2,3 treatment controls were carried out by the attending physicians ≥4 weeks after eradication treatment (test methods and the respective results are summarized in Table S1 , available as Supplementary data at JAC Online). Improvement of symptoms as reported by patients was evaluated and documented by the attending physicians without using a particular scoring sheet or scale.
Even though not reported, poor compliance and any side effects cannot be ruled out.
Ethics
The local ethics review committee confirmed this study was surveillance and hence did not require approval. All data were analysed anonymously.
Statistical analysis
Independence of criteria was tested by x 2 or Fisher's exact tests applying a significance level of 0.05.
Results

Baseline characteristics of patients
Four-hundred-and-eighty-one patients with positive H. pylori culture and phenotypic antimicrobial susceptibility testing were evaluated (data on patients are summarized in Table 1 ). As all patients had undergone prior unsuccessful eradication treatments, the proportions of H. pylori resistant to clarithromycin, metronidazole and levofloxacin were markedly high and associated with the number of treatment failures (Table 2) ; only a few patients (n¼23) carried rifabutin-resistant isolates and none of the strains tested was resistant to amoxicillin or tetracycline. The resistance of H. pylori from patients with peptic ulcer disease was not significantly different from the resistance of H. pylori from patients with non-ulcer diseases (resistance data are summarized in Table S2 ).
Patients with one prior treatment had primarily been administered amoxicillin and clarithromycin (109 out of 149; 73.2%) and patients with two unsuccessful treatments in the past had most often received amoxicillin, clarithromycin and metronidazole (122 out of 215; 56.7%). Nearly half of the patients (50 out of 107; Draeger et al.
46.7%) with three or more prior treatments had taken at least four different antibiotics (antimicrobials used in prior treatments are listed in Table S3 ).
Administered therapies and outcome
Patients carrying H. pylori resistant to clarithromycin and metronidazole (n¼205) had undergone one (n¼53) prior unsuccessful treatment, two (n ¼ 101) prior unsuccessful treatments or three or more (n ¼ 44) prior unsuccessful treatments (for 7 patients the number of prior eradication therapies was unknown). In patients with H. pylori resistant to metronidazole and clarithromycin, treatment with levofloxacin, rifabutin and PPI proved to be most successful (success rate¼80.1%; Figure 1a) ; there was, however, no significant statistical difference when compared with other regimens. Patients with H. pylori resistant to clarithromycin, metronidazole and quinolones (n ¼ 121) had one (n ¼ 25) unsuccessful eradication treatment, two (n ¼ 54) unsuccessful eradication treatments or three or more (n ¼ 40) unsuccessful eradication treatments in the past (for 2 patients the number of prior eradication therapies was unknown). Even though treatments with amoxicillin and PPI (success rate ¼ 79.6%) proved to be most successful in this group of patients (Figure 1b) , none of the various therapies administered was significantly better than the others. Treatments and outcome in patients with either entirely susceptible H. pylori (n ¼ 14) or H. pylori resistant to solely clarithromycin (n ¼ 63); solely metronidazole (n ¼ 40); solely levofloxacin (n ¼ 7); clarithromycin and levofloxacin (n ¼ 20); and metronidazole and levofloxacin (n¼ 11) are summarized in Table S4 .
Six months on, the majority of successfully treated patients were either less symptomatic or asymptomatic (279 out of 336; 83%). Thirty-nine patients (11.6%) did not report any clinical improvement; for the remaining patients, no information was available.
In patients in whom therapy failed, 73.1% (106 out of 145) did not feel any improvement, 20% (n¼ 29) were asymptomatic and for 10 patients no information on symptoms was available.
Neither underlying diseases such as gastritis or peptic ulcer disease (P .0.99) nor patients' sex (P ¼ 0.82) had any impact on treatment outcome.
Discussion
In an estimated 20% of H. pylori-positive patients, empirical firstline therapies, mostly including clarithromycin, fail primarily due to a lack of compliance and antimicrobial resistance of the bacteria. 7 -10 Thus, physicians are prompted to prescribe second-line therapies to eradicate H. pylori. In line with a national guideline, German gastroenterologists are requested to have antimicrobial susceptibility of H. pylori tested not later than after the second therapy failure enabling an antibiogram-adapted therapy.
2,3 Our retrospectively gathered data on 481 patients with at least one unsuccessful treatment in the past show that such susceptibilityguided treatments succeeded in 336 (69.9%) patients. This eradication rate was below treatment success rates reported by others, 11 which might be due to the patient cohort we investigated; more than one-third had two or even more unsuccessful treatments in the past. Other factors such as the grade of gastric inflammation, gastric acid secretion and patients' genetics such as polymorphisms in cytochrome P450 2C19 or IL-1b may also have an impact on successful eradication and might explain why susceptibility-guided treatments fail in 30% of patients. 6, 7, 12, 13 Of note, most patients in our study were female. We and others have shown that women have a higher risk than men to harbour metronidazole-, clarithromycin-and quinolone-resistant H. pylori. 6, 14 Hence, female patients may get prescribed more eradication treatments that may result in more treatment failures.
In patients with double and triple resistant H. pylori, treatment with rifabutin, levofloxacin and PPI or amoxicillin and PPI achieved higher but not significantly better outcomes. A novel quadruple combination of bismuth subcitrate, metronidazole and tetracycline in one capsule with a PPI for 10 days has achieved excellent eradication rates in recent studies. 15 As this combination of drugs, however, was not yet available in Germany during the study period and physicians were required to purchase bismuth subcitrate via international pharmacies abroad, only few patients were More than 80% of the successfully treated patients reported that their symptoms improved. As this percentage is far higher than reported by others, further follow-up is needed to show whether the patients indeed benefitted from eradication treatment. 16 Resistance to macrolides or quinolones may be initiated by the use of these antimicrobials due to any unrelated bacterial infection. Thus, the NRC recommends having susceptibility testing carried out as early as possible. 5, 6 Even though early testing cannot avoid the development of resistance, it at least spares patients the intake of inefficient antibiotics and reduces costs. 17, 18 In case phenotypic antimicrobial susceptibility testing is not feasible and/or available, genotypic testing might be an alternative; it is quick and reliable and several commercial test kits based on realtime PCR methods and reverse hybridization are available. These methods work straight from gastric tissue samples and predict resistance to clarithromycin and/or levofloxacin with high specificity and sensitivity. 19 -22 As resistance to tetracycline and rifabutin is rare and resistance to amoxicillin has not yet been described in Germany, knowledge of resistance to clarithromycin and levofloxacin may be sufficient for an adequate therapy to be selected. If susceptibility testing is not available, physicians may refrain from administering clarithromycin in previously unsuccessfully treated patients. Instead, they may prescribe regimens that are largely unaffected by antimicrobial resistance such as: quadruple therapies including metronidazole, tetracycline, bismuth salt and PPI; combinations of amoxicillin, rifabutin and PPI; or amoxicillin with PPI. 15, 23, 24 In summary, we suggest having antimicrobial susceptibility tested not later than after the second therapy failure. Susceptibility testing is cost-effective, prevents the administration of inefficient antibiotics and enables tailoring of an individual treatment that is successful in 70% of patients.
